Document:

Exhibit 1013 (c)

		
			﻿
		

		
			                          Exhibit 10.13(c)
		

		
			﻿
		

		
			﻿
		

		
			Second Amendment to the Exclusive IP License Agreement for RQ-00000005 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.
		

		
			﻿
		

		
			This is the Second Amendment (“Second Amendment”) to the Exclusive IP License Agreement for RQ-00000005 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on January 2nd, 2017 (the “Second Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
		

		
			RECITALS
		

		
			WHEREAS, the Parties have entered into the Agreement, pursuant to which the Licensor granted Licensee an exclusive worldwide license to RQ-00000005 Technology (as defined in the Agreement);
		

		
			WHEREAS,  the Parties desire to amend the disclosure provisions of the Agreement to reduce the frequency of required meetings.
		

		
			NOW, THEREFORE, in consideration of the mutual covenants set forth herein and for other consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
		

		
			﻿
		

		
			AGREEMENT
		

		
			﻿
		

		
			Section 6.1 of the Agreement is hereby deleted and replaced as follows:
		

		
			6.1 Disclosure. Each Party will provide twice yearly as of “January 1st and July 1st,  a brief report of any Improvements created, conceived, or reduced to practice since the last report, including a list and description of all patent applications pertaining to the Improvements filed since the last report.  In addition, Licensor and Licensee shall meet once per year during the term of this Agreement at a time and place mutually agreed upon between the Parties, which may be telephonically or in person, to disclose Licensor and Licensee Improvements.  In the event there have been no Licensor or Licensee Improvements since the prior meeting, as notified by each Party in writing, no such meeting shall be required.
		

		

		

		 

 

		

			    

		

		
		

		
			﻿
		

		
			IN WITNESS WHEREOF, the Parties have caused this Amendment to the Agreement to be executed by their authorized representatives.
		

			
					
						﻿

					
						 

					
						RaQualia Pharma, Inc.  by:

					
					
						 

					
						 

					
						 

					
						 

					
						/s/ Naoki Tani

				
	
					
						Signature of authorised signatory

					
						 

					
						 

					
						Naoki Tani

				
	
					
						﻿

					
					
						Name of authorised signatory

					
						 

					
						President and CEO__________________________

					
						Title

					
						 

					
						__2017/2/09_______________________________

					
						Date

					
						 

					
						 

					
						 

					
						 

					
						 

				

		
			ARATANA therapeutics, INC by:
		

			
					
						﻿

					
						 

					
						 

					
						 

					
					
						 

					
						_/s/ Steven St. Peter_________________________

					
						Signature of authorised signatory

					
						 

					
						 

					
						Steven St. Peter

				
	
					
						Name of authorised signatory

					
						 

					
						CEO____________________________________

					
						Title

					
						 

					
						1/3/2017________________________________

					
						Date

					
						 

					
						 

				

		
			﻿
		

		
			﻿
		

		 

		

			 

		

		

			2Exhibit 1014 (c)

		
			Exhibit 10.14(c)
		

		
			﻿
		

		
			﻿
		

		
			﻿
		

		
			Second Amendment to the Exclusive IP License Agreement for RQ-00000007 between Aratana Therapeutics Inc. and RaQualia Pharma Inc.
		

		
			﻿
		

		
			This is the Second Amendment (“Second Amendment”) to the Exclusive IP License Agreement for RQ-00000007 dated December 27, 2010 (the “Agreement”) between Aratana Therapeutics Inc., a Delaware corporation (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation (“Licensor”), and is made and entered into between Licensee and Licensor on January 2nd, 2017 (the “Second Amendment Effective Date”). Licensee and Licensor are referred to herein individually as a “Party” and collectively as the “Parties”.
		

		
			RECITALS
		

		
			WHEREAS, the Parties have entered into the Agreement, pursuant to which the Licensor granted Licensee an exclusive worldwide license to RQ-00000007 Technology (as defined in the Agreement);
		

		
			WHEREAS, the Parties desire to amend the disclosure provisions of the Agreement to reduce the frequency of required meetings.
		

		
			NOW, THEREFORE, in consideration of the mutual covenants set forth herein and for other consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:
		

		
			﻿
		

		
			AGREEMENT
		

		
			﻿
		

		
			Section 6.1 of the Agreement is hereby deleted and replaced as follows:
		

		
			6.1 Disclosure. Each Party will provide twice yearly as of “January 1st and July 1st,  a brief report of any Improvements created, conceived, or reduced to practice since the last report, including a list and description of all patent applications pertaining to the Improvements filed since the last report.  In addition, Licensor and Licensee shall meet once per year during the term of this Agreement at a time and place mutually agreed upon between the Parties, which may be telephonically or in person, to disclose Licensor and Licensee Improvements.  In the event there have been no Licensor or Licensee Improvements since the prior meeting, as notified by each Party in writing, no such meeting shall be required.
		

		

		

		 

 

		

			    

		

		
		

		
			﻿
		

		
			IN WITNESS WHEREOF, the Parties have caused this Amendment to the Agreement to be executed by their authorized representatives.
		

			
					
						﻿

					
						 

					
						RaQualia Pharma, Inc.  by:

					
					
						 

					
						 

					
						 

					
						 

					
						/s/ Naoki Tani

				
	
					
						Signature of authorised signatory

					
						 

					
						 

					
						Naoki Tani

				
	
					
						﻿

					
					
						Name of authorised signatory

					
						 

					
						_President & CEO__________________________

					
						Title

					
						 

					
						_2017/2/09________________________________

					
						Date

					
						 

					
						 

					
						 

					
						 

					
						 

				

		
			ARATANA therapeutics, INC by:
		

			
					
						﻿

					
						 

					
						 

					
						 

					
					
						 

					
						_/s/ Steven St. Peter_______________________

					
						Signature of authorised signatory

					
						 

					
						 

					
						Steven St. Peter

				
	
					
						Name of authorised signatory

					
						 

					
						CEO______________________________________

					
						Title

					
						 

					
						_1/3/2017__________________________________

					
						Date

					
						 

					
						 

				

		
			﻿
		

		
			﻿
		

		 

		

			 

		

		

			2Supplemental Indenture

 Exhibit 4.1 
  

 
 AMERICAN MIDSTREAM PARTNERS, LP

 AMERICAN MIDSTREAM FINANCE CORPORATION 

and 
 the Guarantors named herein

  
  

8.500% SENIOR NOTES DUE 2021 
  

 
  

 
 SUPPLEMENTAL
INDENTURE 
 DATED AS OF MARCH 8, 2017 
  

 
 WELLS FARGO
BANK, NATIONAL ASSOCIATION, 
 Trustee 
  

 
  

 

 This SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of March 8,
2017, is among American Midstream Partners, LP, a Delaware limited partnership (the “Company”), American Midstream Finance Corporation, a Delaware corporation (“Finance Corp.” and, together with the Company, the
“Issuers”), each of the parties identified under the caption “Guarantors” on the signature page hereto (the “Guarantors”) and Wells Fargo Bank, National Association, a national banking association, as Trustee. 

RECITALS 
 WHEREAS, the Issuers,
the initial Guarantors and the Trustee entered into an Indenture, dated as of December 28, 2016 (the “Indenture”), pursuant to which the Company has issued $300,000,000 in the aggregate principal amount of 8.500% Senior Notes due 2021
(the “Notes”); 
 WHEREAS, Section 9.01(g) of the Indenture provides that the Issuers, the Guarantors and the Trustee may amend or
supplement the Indenture in order to comply with Section 4.13 or otherwise add guarantees of the Notes, without the consent of the Holders of the Notes; and 

WHEREAS, all acts and things prescribed by the Indenture, by law and by the Certificate of Incorporation and the Bylaws (or comparable
constituent documents) of the Issuers, of the Guarantors and of the Trustee necessary to make this Supplemental Indenture a valid instrument legally binding on the Issuers, the Guarantors and the Trustee, in accordance with its terms, have been duly
done and performed; 
 NOW, THEREFORE, to comply with the provisions of the Indenture and in consideration of the above premises, the
Issuers, the Guarantors and the Trustee covenant and agree for the equal and proportionate benefit of the respective Holders of the Notes as follows: 

ARTICLE 1 
 Section 1.01.
This Supplemental Indenture is supplemental to the Indenture and does and shall be deemed to form a part of, and shall be construed in connection with and as part of, the Indenture for any and all purposes. 

Section 1.02. This Supplemental Indenture shall become effective immediately upon its execution and delivery by each of the Issuers, the
Guarantors and the Trustee. 
 ARTICLE 2 

From this date, by executing this Supplemental Indenture, the Guarantors whose signatures appear below are subject to the provisions of the
Indenture to the extent provided for in Article 10 thereunder. 
 ARTICLE 3 

Section 3.01. Except as specifically modified herein, the Indenture and the Notes are in all respects ratified and confirmed (mutatis
mutandis) and shall remain in full force and effect in accordance with their terms with all capitalized terms used herein without definition having the same respective meanings ascribed to them as in the Indenture. 

 Section 3.02. Except as otherwise expressly provided herein, no duties, responsibilities or
liabilities are assumed, or shall be construed to be assumed, by the Trustee by reason of this Supplemental Indenture. This Supplemental Indenture is executed and accepted by the Trustee subject to all the terms and conditions set forth in the
Indenture with the same force and effect as if those terms and conditions were repeated at length herein and made applicable to the Trustee with respect hereto. 

Section 3.03. THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 

Section 3.04. The parties may sign any number of copies of this Supplemental Indenture. Each signed copy shall be an original, but all of
such executed copies together shall represent the same agreement. Signatures of the parties hereto transmitted by facsimile or .pdf shall be deemed to be their original signatures for all purposes. 

[NEXT PAGE IS SIGNATURE PAGE] 

 IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly
executed, all as of the date first written above. 
  

			
	AMERICAN MIDSTREAM PARTNERS, LP
		
	By:	 	American Midstream GP, LLC, its sole general partner
		
	By:	 	 /s/ Eric T. Kalamaras

	Name:	 	Eric T. Kalamaras
	Title:	 	Senior Vice President and Chief Financial Officer
	
	AMERICAN MIDSTREAM FINANCE CORPORATION
		
	By:	 	 /s/ Eric T. Kalamaras

	Name:	 	Eric T. Kalamaras
	Title:	 	Senior Vice President and Chief Financial Officer

  
 Signature Page to
Supplemental Indenture 

 
			
	Guarantors:
	
	ARGO MERGER GP SUB, LLC
	JP ENERGY PARTNERS, LP
		 	By: Argo Merger GP Sub, LLC, its General Partner
	JP ENERGY CRUDE OIL SERVICES, LLC
	JP ENERGY PRODUCTS SUPPLY, LLC
	JP FALCO, LLC
	JP ENERGY STORAGE, LLC
	JP ENERGY PERMIAN, LLC
	JP ENERGY REFINED PRODUCTS, LLC
	JP ENERGY ATT, LLC
	JP ENERGY CADDO, LLC
	PINNACLE PROPANE, LLC
	PINNACLE PROPANE EXPRESS, LLC
	ALLIANT GAS, LLC
	JP LIQUIDS, LLC
		
	By:	 	 /s/ Patrick J. Welch

	Name:	 	Patrick J. Welch
	Title:	 	Executive Vice President and Chief Financial Officer

  
 Signature Page to
Supplemental Indenture 

 
			
	JP ENERGY SERVICES, LLC
		
	By:	 	 /s/ Patrick J. Welch

	Name:	 	Patrick J. Welch
	Title:	 	Executive Vice President and Chief Financial Officer

  
 Signature Page to
Supplemental Indenture 

 
			
	JP ENERGY ST. CROIX, LLC
		
	By:	 	 /s/ Patrick J. Welch

	Name:	 	Patrick J. Welch
	Title:	 	Executive Vice President and Chief Financial Officer

  
 Signature Page to
Supplemental Indenture 

			
	 WELLS FARGO BANK, NATIONAL ASSOCIATION,

as Trustee

		
	By:	 	 /s/ John C. Stohlmann

	Name:	 	 John C. Stohlmann

	Title:	 	 Vice President

  
 Signature Page to
Supplemental Indenture

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]